Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 530239 | NSE Symbol : SUVEN | ISIN : INE495B01038 | Industry : Healthcare |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
16-Jan-2025	24-Jan-2025	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31 2024 and related matters
21-Oct-2024	29-Oct-2024	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve consider and approve among other things inter alia and take on record: Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30 2024 Financial results for quarter & half-year ended 30/09/2024 (As Per BSE Announcement dated on 29.10.2024)
29-Jul-2024	05-Aug-2024	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2024 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Monday 05th August 2024 at 12:00 p.m. to consider among other matters inter alia and approve the following matter(s): The Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter ended June 30 2024 and related matters. Unaudited Standalone & Consolidated financial results for quarter ended June 30, 2024 (As per BSE Announcement Dated on 05/08/2024)
29-Apr-2024	06-May-2024	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2024 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the 6th May, 2024 at 5:30 p.m. at the Registered Office, SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, among other matters, inter alia, and approve the following matter(s): The Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31, 2024 and related matters Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2024 as per PIT Code of the Company. Trading window will be opened from 9th May, 2024. Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2024 Outcome of the Board Meeting Re-appointment of Managing Director Annual General Meeting & Closure of Register of Members & Share Transfer Books (As Per BSE Announcement Dated on 06/05/2024)
23-Jan-2024	30-Jan-2024	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 inter alia to consider and approve to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter ended December 31 2023 and other business matters. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we hereby inform that the Board of Directors of Suven Life Sciences Limited at its meeting held today i.e., January 30, 2024, has inter alia, transacted the following businesses: - Appointment of Dr. Vajja Sambasiva Rao as Non-Executive Additional Independent Director of the Company and noting of resignation of Shri Gopalakrishna Muddusetty as Non-Executive Independent Director of the Company. Outcome of the Board Meeting Q3 Results FY 2023-24 (As per BSE Announcement Dated on 30/01/2024)
27-Oct-2023	04-Nov-2023	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter and half year ended September 30 2023 and related matters Enclosed Unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30, 2023 (As Per BSE Announcement Dated on 04.11.2023)
01-Aug-2023	08-Aug-2023	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2023 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Tuesday August 08 2023 at 11:30 a.m. at the Registered Office of the Company at SDE Serene Chambers 6th Floor Road No 5 Banjara Hills Hyderabad-500034 to consider among other things inter alia and take on record the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter ended June 30 2023 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from July 01 2023 as per PIT Code of the Company. Trading window will be opened from August 11 2023. Outcome of Board Meeting (As Per BSE Announcement dated on 08.08.2023)
02-May-2023	09-May-2023	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2023 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Tuesday the 09th May 2023 at 11:30 a.m. at the Registered Office of the Company at SDE Serene Chambers 6th Floor Road No 5 Banjara Hills Hyderabad-500034 to consider among other things inter alia and take on record the following matter(s): To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and year ended 31st March 2023 and related matters. With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. May 09, 2023, approved the following along with other business matters. Took on record and approved the Audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and Financial Year ended 31st March, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Audit Reports of the Statutory Auditors. With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. May 09, 2023, approved the following along with other business matters. 1) Took on record and approved the Audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter and Financial Year ended 31st March, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Audit Reports of the Statutory Auditors. 2) Re-appointment of Independent Directors 3) Closure of Register of Members & Share Transfer Books 4) e-Annual General Meeting (AGM) (As Per BSE Announcement Dated on 09.05.2023)
25-Jan-2023	02-Feb-2023	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2023 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Thursday February 02 2023 at 11:30 a.m. at the Registered Office of the Company at SDE Serene Chambers 6th Floor Road No 5 Banjara Hills Hyderabad-500034 to consider among other things inter alia and take on record the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter ended December 31 2022 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from January 01 2023 as per PIT Code of the Company. Trading window will be opened from February 06 2023. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company at its meeting held today i.e. February 02, 2023, has taken on record and approved Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter ended December 31, 2022. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for quarter ended December 31, 2022. b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the News Release of our company Update on patents during this period are accessible to everyone at below mentioned web link: www.suven.com/Patentupdates.aspx (As Per BSE Announcement dated on 02.02.2023)
03-Nov-2022	10-Nov-2022	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter and half-year ended September 30 2022 and related matters.
07-Oct-2022	12-Oct-2022	Right Issue	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/10/2022 inter alia to consider and approve We inform you that a meeting of the Rights Issue Committee of the Board of Directors of the Company will be held on Wednesday October 12 2022 to inter alia consider and approve the terms and conditions of the rights issue including determination of the issue price and record date for the issuance of equity shares to be offered in the rights issue. Board considered and approved the following terms and conditions of the Rights issue: a) Instrument: Fully paid-up equity shares of face value of Re.1 each ('Equity Shares') b) Total number of Equity Shares and Rights Issue size: 7,26,91,239 fully paid-up Equity Shares each for amount aggregating to Rs.399.80/- Crores (Three Hundred and Ninety Nine crore Eighty Lakh). c) Issue Price: Rs. 55/- per fully paid-up Equity Share [including a premium of Rs.54/- per Equity Share. d) Rights entitlement ratio: 1:2 [1 (One) Rights Equity Share for every 2 (Two) fully paid-up Equity Shares held by the Eligible Equity Shareholders of the Company, as on the record date]. If the shareholding of the Eligible Equity Shareholder is 2 (Two) or more, such shareholders will be entitled to at least 1 (One) Equity Share. e) ISIN for Rights Entitlement: INE495B20012 f) Other terms of the Rights Issue (including fractional and zero entitlements): To be included in the Letter of Offer to be filed by the Company. g) Record date: October 18, 2022 for the purpose of determining the equity shareholders entitled to receive the rights entitlement in the Rights Issue ('Eligible Equity Shareholders') (As Per BSE Bulletin Dated on 12.10.2022) Rights Issue Committee of the Board of Directors of the Company, at their meeting held today i.e. on October 12, 2022, inter-alia, considered and approved the following terms and conditions of the Rights issue. This is to inform that the Rights Issue committee of the Board of Directors at its meeting held today i.e. October 12, 2022 has fixed Tuesday, October 18, 2022 as the 'Record Date' for the purpose of determining the equity shareholders entitled to receive rights entitlements in the Rights Issue of the Company approved by the Board of Directors at its meeting held on June 24, 2022 on the terms & conditions as approved by the Rights Issue committee of Board of Directors on October 12, 2022. (As per BSE Announcement Dated on 12/10/2022) In furtherance to our intimation dated October 12, 2022 informing approval of the terms and conditions of the Rights Issue, we wish to inform that Rights Issue Committee of the Board of Directors of the Company, at their meeting held today i.e. Tuesday, October 18, 2022, inter-alia considered and approved the following: a) Issue period: 1. Issue Opening Date: Monday, October 31, 2022 2. Issue Closing Date: Thursday, November 10, 2022. b) the Letter of Offer (LOF) to be filed with Securities and Exchange Board of India, BSE Limited and National Stock Exchange of India Limited. (As per BSE Announcement Dated on 18/10/2022)
18-Jul-2022	26-Jul-2022	Quarterly Results	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2022 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Tuesday the 26th July 2022 at 11:30 a.m. at the Registered Office of the Company at SDE Serene Chambers 6th Floor Road No 5 Banjara Hills Hyderabad-500034 to consider among other things inter alia and take on record the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter ended 30th June 2022 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st July 2022 as per PIT Code of the Company. Trading window will be opened from 29th July 2022. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company at its meeting held today i.e. 26th July, 2022, has taken on record and approved Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS along with review reports of the Statutory Auditors for the quarter ended 30th June, 2022. We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for quarter ended 30th June, 2022. b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the News Release of our company (As Per BSE Announcement dated on 26.07.2022)
20-Jun-2022	24-Jun-2022	Right Issue	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/06/2022 inter alia to consider and approve With reference to above subject and pursuant to Regulation 29(1)(d) of the SEBI LODR Regulations this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday 24th June 2022 at 11:00 a.m. inter alia to consider matters related to raising of funds through issue of equity shares of the Company on rights basis to the existing equity shareholders of the Company in accordance with provisions of Companies Act 2013 and SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended and other matters related/ incidental thereto including the constitution of a Committee of Board of Directors namely Rights Issue Committee to implement the proposal of Rights Issue. The 'Trading Window' for dealing in the securities of the Company shall remain closed from 21st June 2022 to 26th June 2022 (both days inclusive) for the Directors Promoters other Designated Persons and immediate relatives of Designated Persons. 1) Approved the raising of funds, through issuance and allotment of equity shares having face value of Rs 1 each up to an aggregate amount of 400 Crores (Rupees Four Hundred Crores) on rights basis and on such terms (as decided by the Board or a duly constituted committee of the Board, at a later date) to the eligible equity shareholders of the Company, as on the record date (to be notified subsequently), subject to receipt of regulatory/ statutory approvals, in accordance with the applicable laws including the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI LODR Regulations and the Companies Act, 2013, and rules and regulations made thereunder, each as amended from time to time and approved other related matters including the constitution of a Rights Issue Committee to implement the proposal of Rights Issue. (As Per BSE Announcement dated on 24.06.2022)
30-Apr-2022	07-May-2022	Accounts	SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2022 inter alia to consider and approve Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and year ended 31st March 2022 and related matters. With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. May 07, 2022, approved the following along with other business matters. (As Per BSE Announcement Dated on 07.05.2022)
28-Mar-2022	28-Mar-2022	Conversion	In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, we wish to inform that, the Board of Directors of the Company at its meeting held today i.e. 28th March, 2022 has approved the conversion of 1,81,00,000 fully paid warrants and issued & allotted 1,81,00,000 (One crore eighty one lakh) Equity Shares of Rs.1/- each to 'Jasti Property and Equity Holdings Private Limited (In its capacity as sole trustee of Jasti Family Trust)', promoter group entity at an issue price of Rs. 81.57/- per share on preferential basis in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

1 2

LOGIN HERE

Suven Life Sciences Ltd

Board Meeting